Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin

Anti-Cancer Drugs

Volumn 21, Issue 3, 2010, Pages 313-319

  Petrioli, Roberto ^a   Bargagli, Gianluca ^a   Lazzi, Stefano ^b   Pascucci, Alessandra ^a   Francini, Edoardo ^a   Bellan, Cristiana ^b   Conca, Raffaele ^a   Martellucci, Ignazio ^a   Fiaschi, Anna Ida ^c   Lorenzi, Bruno ^b   Francini, Guido ^a  

^a Medical Oncology Section   (Italy)

^b Department of Human Pathology and Oncology ^*

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

Capecitabine; Colorectal cancer; Liver metastases; Oxaliplatin; Thymidine phosphorylase; Thymidylate synthase

Indexed keywords

CAPECITABINE; DEXAMETHASONE; FLUOROURACIL; LOPERAMIDE; OXALIPLATIN; SEROTONIN 3 ANTAGONIST; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ABDOMINAL PAIN; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DRUG SAFETY; FATIGUE; FEMALE; GENE EXPRESSION REGULATION; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; LIVER METASTASIS; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ORAL REHYDRATION THERAPY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

EID: 76649099757     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328334d88a     Document Type: Article

References (34)

1. Scheithauer W, Kornek GV, Raderer M, Schüll B, Schmid K, Kovats E, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21:1307-1312.
2. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 12:2084-2091.
3. Borner M, Koeberle D, Von Moos R, Saletti P, Rauch D, Hess V, et al, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2008; 19:1288-1292.
4. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013-2019.
5. Diaz Rubio E, Tabernero J, Gomez-Espana A, Massuti B, Sastre J, Chaves M, et al, Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. Phase III study of capecitabine plus oxaliplatin compared with continuousinfusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007; 25:4224-4230.
6. Sobrero A, Aschele C, Guglielmi AP, Mori AM, Melioli GG, Rosso R, et al. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J Natl Cancer Inst 1993; 85:1937-1944.
7. Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 1998; 16:1795-1802.
8. Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 2000; 18:1337-1345.
9. Lokich J. Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule. Cancer Invest 2004; 22:713-717.
10. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, et al. Immunoistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracilbased chemotherapy. J Clin Oncol 1999; 17:1760-1770.
11. Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, et al. Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 2000; 82:560-567.
12. Miyadera K, Sumizawa T, Haraguchi M, Yoshida H, Konstanty W, Yamada Y, et al. Role of thymidyne phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 1995; 55:1687-1690.
13. Takebayashi Y, Akiyama S, Akiba S, Miyadera K, Sumizawa T, Yamada Y, et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996; 88:1110-1117.
14. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidyne phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998; 58:685-690.
15. Hsu SM, Raine L, Fanger H. A comparative study of the peroxidaseantiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 1981; 75:734-738.
16. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
17. Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/ leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008; 26:5910-5917.
18. Ho J, Gill S. Impact of capecitabine-related toxicities on chemotherapeutic dose delivery in colorectal cancer [abstr 4101]. J Clin Oncol 2008; 26.
19. Petrioli R, Pascucci A, Francini E, Marsili S, Fiaschi AI, Civitelli S, et al. Multidisciplinary Oncology Group on Gastrointestinal Tumors. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors. Anticancer Drugs 2008; 19:91-96.
20. Moreno Solorzano I, Ibeas-Rollan R, Monzo-Planella M, Moreno Solorzano J, Martinez-Rodenas F, Pou-Sanchis E, et al. Two doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer. Clin Colorectal Cancer 2007; 9:634-640.
21. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protractedinfusion fluorouracil and weekly leucovorin. J Clin Oncol 1997; 15: 3223-3229.
22. Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL,Wadler S, et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998; 4:2371-2376.
23. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6:1322-1327.
24. Corsi DC, Ciaparrone M, Zannoni G, Mancini M, Cassano A, Specchia M, et al. Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer. Eur J Cancer 2002; 38:527-534.
25. Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renee N, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994; 30A:1517-1522.
26. Soong R, Shah N, Salto-Tellez M, Tai BC, Soo RA, Han HC, et al. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 2008; 19:915-919.
27. Uchida K, Danenberg PV, Danenberg KD, Grem JL. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. BMC Cancer 2008; doi: 10.1186/1471-2407-8-386.
28. Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, et al. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24:4069-4077.
29. Findlay MP, Cunningham D, Morgan G, Clinton S, Hardcastle A, Aherne GW. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 1997; 75:903-909.
30. Diep CB, Teixeira MR, Thorstensen L,Wiig JN, Eknaes M, Nesland JM, et al. Genome characteristics of primary carcinomas, local recurrences, carcinomatoses, and liver metastases from colorectal cancer patients. Mol Cancer 2004; 3:6.
31. Cartwright T, Lopez T, Vukelja SJ, Encarnacion C, Boehm KA, Asmar L. Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer 2005; 5:50-56.
32. Koopman M, Vanderbosch S, Nagtegaal ID, Van Krieken JH, Punt CJ. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Eur J Cancer 2009; 45:1935-1949.
33. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004; 22:529-536.
34. Smorenburg CH, Peters GJ, Van Groeningen CJ, Noordhuis P, Smid K, Van Riel AM, et al. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluorouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann Oncol 2006; 17:35-42.